Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 21;17(13):2083.
doi: 10.3390/cancers17132083.

Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer

Affiliations

Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer

Ana Majić et al. Cancers (Basel). .

Abstract

Background: The role of neoadjuvant endocrine therapy (NET) in patients with luminal tumors is still not well defined in everyday clinical practice. To assess the efficacy of combination NET, we analyzed the outcomes of fulvestrant and aromatase inhibitors (AI) in combination in a real-world population. Methods: This was a single-arm, retrospective longitudinal study of the total population of patients diagnosed with locoregionally advanced, clinical stage II-III, HR+ HER2-, luminal-type eBC, who were treated with the neoadjuvant combination of fulvestrant and AI between 2019 and 2024 at the Clinical University Hospital of Split, Croatia. Results: We enrolled 44 patients in the intention-to-treat (ITT) population, while 34 completed NET and surgery (per-protocol population; PPP). The median duration of NET was 11 months (interquartile range [IQR] of 9-16 months). The best radiological objective response rate (partial or complete response) was achieved by 30 (68.2%) in ITT, and 26 (76.5%) in PPP, defined by radiological examination, breast ultrasound, or MR. In the PPP, the minimal or moderate pathological response according to residual cancer burden (I or II) was observed in 29 (85.3%) patients. The median of absolute changes in Ki-67 was -5 (95% CI: -9 to 0), and the median of relative Ki67 changes was -40% (95% CI: -72% to 0%). Post-surgical Ki-67 was significantly predicted by initial Ki-67, positive lymph nodes, and time from diagnosis to the initiation of NET. Treatment was well tolerated, with no therapy discontinuation or dose reductions needed due to toxicity. The most commonly reported side effects included musculoskeletal pain (45.5%), asthenia (34.1%), and hot flashes (29.5%). Conclusions: Dual hormonal therapy with fulvestrant and AI is an active, easily given, non-toxic, promising neoadjuvant treatment in real-world patients with locally advanced luminal-type eBC who are not candidates for chemotherapy.

Keywords: Ki-67 antigen; aromatase inhibitors; breast neoplasms; endocrine therapy; fulvestrant; neoadjuvant therapy; real-world evidence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Croatian Institute of Public Health Incidence of Cancer in Croatia 2022. [(accessed on 5 June 2025)]. Available online: https://www.hzjz.hr/periodicne-publikacije/incidencija-raka-u-hrvatskoj-...
    1. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., Margolese R.G., Hoehn J.L., Vogel V.G., Dakhil S.R., et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 2008;26:778–785. doi: 10.1200/JCO.2007.15.0235. - DOI - PubMed
    1. Loibl S., Jackisch C., Schneeweiss A., Schmatloch S., Aktas B., Denkert C., Wiebringhaus H., Kümmel S., Warm M., Paepke S., et al. Dual HER2-Blockade with Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer: A Subanalysis of Data from the Randomized Phase III GeparSepto Trial. Ann. Oncol. 2017;28:497–504. doi: 10.1093/annonc/mdw610. - DOI - PubMed
    1. Schmid P., Cortes J., Dent R., Pusztai L., McArthur H., Kummel S., Bergh J., Denkert C., Park Y.H., Hui R., et al. Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2022;386:556–567. doi: 10.1056/NEJMoa2112651. - DOI - PubMed

LinkOut - more resources